Cambridge Epigenetix Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Cambridge Epigenetix's estimated annual revenue is currently $21.4M per year.(i)
  • Cambridge Epigenetix's estimated revenue per employee is $155,000

Employee Data

  • Cambridge Epigenetix has 138 Employees.(i)
  • Cambridge Epigenetix grew their employee count by 23% last year.

Cambridge Epigenetix's People

NameTitleEmail/Phone
1
Director Research & DevelopmentReveal Email/Phone
2
Lab TechReveal Email/Phone
3
ChairReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$21.4M13823%N/AN/A
Add Company

What Is Cambridge Epigenetix?

Cambridge Epigenetix aims to change the way medicine is practised by reducing several routine and important diagnostic screening tests to a simple blood draw using the power of the 5-hydroxymethylcytosine (5hmC) epigenetic modification. We utilise innovative technologies, often based on fundamental chemistry, to detect the epigenetic biomarkers that will be most useful in clinical settings. Spun-out of the University of Cambridge in 2012, the Company was founded by Professor Sir Shankar Balasubramanian (co-inventor of Solexa sequencing) and Dr Bobby Yerramilli-Rao to commercialise its founding technology, oxidative bisulfite sequencing (oxBS-Seq), which enables users to quantify, and discriminate between, functionally-distinct DNA modifications – impossible with traditional bisulfite methods. Cambridge Epigenetix is a privately held company headquartered in Cambridge, UK, supported by several high-profile investors: GV (Google Ventures), Sequoia, Syncona, New Science Ventures and the University of Cambridge. The Company is seeking partnerships across a broad range of applications in life sciences, as well as developing its own pipeline. For more information, visit www.cambridge-epigenetix.com or email [email protected].

keywords:N/A

N/A

Total Funding

138

Number of Employees

$21.4M

Revenue (est)

23%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Cambridge Epigenetix News

2021-11-03 - Cambridge Epigenetix raises $88m Series D financing to advance DNA sequencing technology platform

Cambridge Epigenetix raises $88m Series D financing to advance DNA sequencing technology platform 03-11-2021 Cambridge Epigenetix (CEGX), a life sciences tools and technology company revolutionising genome sequencing, has announced the signing of an $88 million Series D financing, bringing the ...

2021-11-03 - Cambridge Epigenetix raises $88m Series D financing to advance DNA sequencing technology platform

Cambridge Epigenetix raises $88m Series D financing to advance DNA sequencing technology platform 03-11-2021 Cambridge Epigenetix (CEGX), a life sciences tools and technology company revolutionising genome sequencing, has announced the signing of an $88 million Series D financing, bringing the ...

2016-03-17 - Google’s GV leads $21M Series B in bioscience firm Cambridge Epigenetix

VC firm GV (née Google Ventures) has made another investment in Europe — its seventh — leading a $21 million Series B round for epigenetic sequencing tech company and Cambridge University spin-out, Cambridge Epigenetix. The U.K.-based bioscience company makes DNA modification analysis tools for ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$33.5M138-3%$10.8M
#2
$34.5M138N/AN/A
#3
$21.4M138-18%$233M
#4
$28.3M138-9%N/A
#5
$24.8M138-1%N/A